1-11 of 11
Manuel Ugidos
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of Mutational Landscape and Biomarkers on Response of Luspatercept (ACE-536) Treatment of Anemia in Non-Transfusion Dependent IPSS-R Lower Risk MDS Japanese Subjects (ACE-536-MDS-003- a Ph2 single-arm study)

Bijay Shankar Jaiswal, Manuel Ugidos, Hiroshi Kosugi, Kosei Matsue, Hiromi Murakami, Jin Hayakawa, Daniel Lopes de Menezes, Anita K. Gandhi, Rajasekhar N.V.S. Suragani
Journal: Blood
Blood (2024) 144 (Supplement 1): 6725.
https://doi.org/10.1182/blood-2024-201883
Published: 2024
Journal Articles

Luspatercept Reduces Clonal Hematopoiesis-Associated Cardiac Stress Via Modulation of mTORC1 and Inflammatory Signaling Pathways

Maroof Hasan, Shahid Tannu, Shikha Saini, Manuel Ugidos, Guillermo Garcia-Manero, Uwe Platzbecker, Ching-Pin Chang, Anita K. Gandhi, Ricardo Garcia, Rajasekhar N.V.S. Suragani
Journal: Blood
Blood (2024) 144 (Supplement 1): 4046.
https://doi.org/10.1182/blood-2024-194241
Published: 2024
Journal Articles

Clonal Dynamics of Gene Mutations during Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML): Outcomes from the QUAZAR AML-001 Trial

Daniel Lopes De Menezes, Manuel Ugidos Guerrero, Arnaud Amzallag, Wendy L. See, Alberto Risueno, Charalampos Kyriakopoulos, Rajasekhar N.V.S. Suragani, Barry S. Skikne, C.L. Beach, Thomas Prebet, Maria Teresa Voso, Andre C. Schuh, Gail J. Roboz, Hartmut Döhner, Andrew H. Wei, Anita K. Gandhi
Journal: Blood
Blood (2023) 142 (Supplement 1): 1582.
https://doi.org/10.1182/blood-2023-187651
Published: 2023
Journal Articles

Improvement of Underlying Disease Pathophysiology of Ineffective Erythropoiesis in Non-Transfusion-Dependent (NTD) Patients with β-Thalassemia Receiving Luspatercept: Biomarker Analysis from the BEYOND Trial

Manuel Ugidos Guerrero, Sujit Sheth, Olivier Hermine, Sadanand Vodala
Journal: Blood
Blood (2023) 142 (Supplement 1): 1104.
https://doi.org/10.1182/blood-2023-179122
Published: 2023
Journal Articles

Impact of Genomic Landscape and Mutational Burden on Primary Endpoint Responses in the COMMANDS Study

Rami S. Komrokji, Manuel Ugidos Guerrero, Guillermo Garcia-Manero, Amer M. Zeidan, Uwe Platzbecker, Sheida Hayati, Sadanand Vodala
Journal: Blood
Blood (2023) 142 (Supplement 1): 4591.
https://doi.org/10.1182/blood-2023-178689
Published: 2023
Journal Articles

Luspatercept Modulates Inflammation in the Bone Marrow, Restores Effective Erythropoiesis/Hematopoiesis, and Provides Sustained Clinical Benefit Versus Epoetin Alfa (EA): Biomarker Analysis from the Phase 3 COMMANDS Study

Sheida Hayati, Amer M. Zeidan, Guillermo Garcia-Manero, Uwe Platzbecker, Aarif Ahsan, Amit K. Verma, Srinivas Aluri, Manuel Ugidos Guerrero, Anita K. Gandhi, Rajasekhar N.V.S. Suragani, Sadanand Vodala
Journal: Blood
Blood (2023) 142 (Supplement 1): 1845.
https://doi.org/10.1182/blood-2023-178674
Published: 2023
Journal Articles

Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial

Danny V Jeyaraju, Sheida Hayati, Ann Polonskaia, Maryam Alapa, Manuel Ugidos, Andrew Browne, Alberto Risueño, Patrick Hagner, Vikas Gupta, Moshe Talpaz, Christopher Hernandez, Vincent Chia, Patricia Martin-Regueira, Daniel Lopes de Menezes, Ross La Motte-Mohs, Rajasekhar NVS Suragani, Anita K. Gandhi
Journal: Blood
Blood (2022) 140 (Supplement 1): 3865–3867.
https://doi.org/10.1182/blood-2022-166407
Published: 2022
Journal Articles

Investigations into the Mechanisms and Clinical Implications of Modulation of Hepcidin Levels By Luspatercept in TD MDS and TD b-Thalassemia

Aarif Ahsan, Wei Fang, Manuel Ugidos, Danny V Jeyaraju, Pierre Fenaux, Uwe Platzbecker, Olivier Hermine, John B. Porter, Rajasekhar N.V.S. Suragani, Sadanand Vodala, Anita K. Gandhi
Journal: Blood
Blood (2022) 140 (Supplement 1): 8188–8189.
https://doi.org/10.1182/blood-2022-166559
Published: 2022
Journal Articles

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine

Clinical Trials & Observations
Hartmut Döhner, Andrew H. Wei, Gail J. Roboz, Pau Montesinos, Felicitas R. Thol, Farhad Ravandi, Hervé Dombret, Kimmo Porkka, Irwindeep Sandhu, Barry Skikne, Wendy L. See, Manuel Ugidos, Alberto Risueño, Esther T. Chan, Anjan Thakurta, C.L. Beach, Daniel Lopes de Menezes
Journal: Blood
Blood (2022) 140 (15): 1674–1685.
https://doi.org/10.1182/blood.2022016293
Published: 2022
Includes: Supplemental data
Journal Articles

Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance

Hartmut Döhner, Andrew H. Wei, Gail J. Roboz, Pau Montesinos, Felicitas R Thol, Farhad Ravandi, Hervé Dombret, Kimmo Porkka, Irwindeep Sandhu, Barry Skikne, Wendy L. See, Manuel Ugidos, Alberto Risueño, Esther Chan, Anjan Thakurta, C.L. Beach, Daniel Lopes de Menezes
Journal: Blood
Blood (2021) 138 (Supplement 1): 804.
https://doi.org/10.1182/blood-2021-147465
Published: 2021
Journal Articles

Luspatercept Redistributes Body Iron to the Liver in Transfusion-Dependent-Thalassemia (TDT) during Erythropoietic Response

Maciej W. Garbowski, Manuel Ugidos, Alberto Risueño, Rajasekhar N.V.S. Suragani, Jeevan K. Shetty, Sadanand Vodala, Anjan Thakurta, Martin Schwickart, John B. Porter
Journal: Blood
Blood (2021) 138 (Supplement 1): 761.
https://doi.org/10.1182/blood-2021-145975
Published: 2021